Madrigal Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Madrigal Pharmaceuticals has a total shareholder equity of $850.8M and total debt of $117.2M, which brings its debt-to-equity ratio to 13.8%. Its total assets and total liabilities are $1.1B and $231.5M respectively.
Key information
13.8%
Debt to equity ratio
US$117.18m
Debt
Interest coverage ratio | n/a |
Cash | US$1.06b |
Equity | US$850.76m |
Total liabilities | US$231.52m |
Total assets | US$1.08b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: YDO1's short term assets ($1.1B) exceed its short term liabilities ($114.3M).
Long Term Liabilities: YDO1's short term assets ($1.1B) exceed its long term liabilities ($117.2M).
Debt to Equity History and Analysis
Debt Level: YDO1 has more cash than its total debt.
Reducing Debt: YDO1's debt to equity ratio has increased from 0% to 13.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: YDO1 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if YDO1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.